良性前列腺增生：碧萝芷®补充剂可改善前列腺症状和残余膀胱容量。
Benign prostatic hypertrophy: Pycnogenol® supplementation improves prostate symptoms and residual bladder volume.
机构信息
IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy.
International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy.
出版信息
Minerva Med. 2018 Aug;109(4):280-284. doi: 10.23736/S0026-4806.18.05572-6.
BACKGROUND
The aim of this study was to evaluate the efficacy of Pycnogenol® supplementation in terms of safety and tolerability in the setting of preclinical or borderline, initial symptoms of benign prostatic hyperthrophy (BPH), in otherwise healthy subjects, using Pycnogenol® over a period of 60 days.
METHODS
Seventy-five healthy men with symptoms and signs of initial BPH were included. The subjects were divided into three groups: 1) control group using only the standard management (SM); 2) a group using SM plus Pycnogenol® 150 mg/day; 3) a group using standard pharmacological management.
RESULTS
BPH symptoms like emptying, frequency, intermittency, urgency, weak flow, straining, nocturia, were all significantly improved with Pycnogenol® (P<0.05) and the difference with both control groups was statistically significant (P<0.05).
CONCLUSIONS
Pycnogenol® may be an important option for self-management of BPH in otherwise healthy men.
背景
本研究旨在评估碧萝芷®在预防或治疗初期良性前列腺增生（BPH）症状，或在健康个体出现轻度 BPH 症状时，使用碧萝芷®补充剂 60 天的安全性和耐受性。
方法
纳入 75 名有 BPH 初期症状和体征的健康男性。将受试者分为三组：1）对照组仅采用标准管理（SM）；2）一组采用 SM 加碧萝芷® 150mg/天；3）一组采用标准药物治疗。
结果
碧萝芷®显著改善 BPH 症状，如排空、频率、间歇性、紧迫性、弱流、费力、夜尿症等（P<0.05），与对照组相比差异具有统计学意义（P<0.05）。
结论
碧萝芷®可能是健康男性自我管理 BPH 的重要选择。
Zotero 插件